Thermo Fisher Scientific (NYSE:TMO) Sets New 1-Year High After Strong Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) hit a new 52-week high during trading on Thursday following a better than expected earnings announcement. The stock traded as high as $705.79 and last traded at $693.9840, with a volume of 4,049,061 shares traded. The stock had previously closed at $687.37.

The medical research company reported $6.68 earnings per share for the quarter, beating analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The firm had revenue of $12.14 billion during the quarter, compared to analyst estimates of $11.95 billion. During the same period last year, the firm posted $5.79 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 9.1% compared to the same quarter last year.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations. Thermo Fisher reported adjusted earnings of $6.68 per share versus the $6.40 consensus, while revenue rose 9.1% year over year to $12.14 billion, topping estimates of $11.95 billion. TMO Q3 deep dive: pharma demand, AI integration, and end-market recovery drive momentum
• Positive Sentiment: Analysts raised their valuation targets. TD Cowen increased its target to $810 and maintained a buy rating, while Stifel raised its target to $775 and Baird lifted its target to $756 with an outperform rating. These revisions imply meaningful upside from recent trading levels. TD Cowen analyst ratings
• Positive Sentiment: Improving end markets support the growth outlook. Investor commentary highlighted a broad-based recovery across life-science markets, including pharmaceutical demand, AI-related applications and other research tools. Erste Group also modestly raised its FY2027 EPS estimate to $27.58 from $27.51. Thermo Fisher benefits on broad-based recovery
• Neutral Sentiment: Secular market growth provides a longer-term tailwind. Industry forecasts call for strong expansion in next-generation sequencing kits and peptide synthesis, markets in which Thermo Fisher participates, although these reports do not directly change near-term earnings. NGS kits market forecast
• Negative Sentiment: Options activity signals caution. Heavy put-option buying indicates that some traders are hedging against, or positioning for, a pullback. The muted reaction to the earnings beat may also reflect elevated expectations and a relatively rich valuation. Thermo Fisher stock sees heavy put option buying

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Guggenheim initiated coverage on shares of Thermo Fisher Scientific in a report on Thursday, October 15th. They issued a “buy” rating for the company. Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $650.00 to $730.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Royal Bank Of Canada upped their price objective on Thermo Fisher Scientific from $580.00 to $730.00 and gave the company a “sector perform” rating in a research report on Thursday. Piper Sandler began coverage on Thermo Fisher Scientific in a research note on Wednesday, September 9th. They issued an “overweight” rating for the company. Finally, Sanford C. Bernstein initiated coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $681.00.

Insider Activity

In related news, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the sale, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at $1,734,546.46. This represents a 12.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares of the company’s stock, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 73,768 shares of company stock worth $44,122,820 in the last 90 days. Company insiders own 0.33% of the company’s stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several hedge funds and other institutional investors have recently modified their holdings of the business. Tsfg LLC lifted its position in shares of Thermo Fisher Scientific by 20.4% during the second quarter. Tsfg LLC now owns 112 shares of the medical research company’s stock worth $56,000 after purchasing an additional 19 shares during the last quarter. Renasant Bank grew its holdings in shares of Thermo Fisher Scientific by 1.0% in the second quarter. Renasant Bank now owns 1,934 shares of the medical research company’s stock worth $970,000 after purchasing an additional 20 shares during the last quarter. Strengthening Families & Communities LLC grew its holdings in shares of Thermo Fisher Scientific by 0.4% in the third quarter. Strengthening Families & Communities LLC now owns 4,721 shares of the medical research company’s stock worth $3,187,000 after purchasing an additional 21 shares during the last quarter. TCI Wealth Advisors Inc. increased its stake in Thermo Fisher Scientific by 5.4% in the 1st quarter. TCI Wealth Advisors Inc. now owns 431 shares of the medical research company’s stock worth $212,000 after buying an additional 22 shares during the period. Finally, Legacy Wealth Managment LLC ID increased its stake in Thermo Fisher Scientific by 78.6% in the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after buying an additional 22 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Down 0.4%

The business’s fifty day moving average is $645.72 and its two-hundred day moving average is $554.80. The company has a market cap of $249.20 billion, a P/E ratio of 27.37, a price-to-earnings-growth ratio of 2.81 and a beta of 0.87. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.18 and a current ratio of 1.81.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.